tailieunhanh - báo cáo hóa học:" Differential hRad17 expression by histologic subtype of ovarian cancer"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Differential hRad17 expression by histologic subtype of ovarian cancer | Young et al. Journal of Ovarian Research 2011 4 6 http content 4 1 6 JOURNAL OF OVARIAN RESEARCH RESEARCH Open Access Differential hRad17 expression by histologic subtype of ovarian cancer Jennifer L Young2 E Colin Koon3 Joseph Kwong4 William R Welch5 Michael G Muto1 Ross S Berkowitz1 and Samuel C Mok6 Abstract Background In the search for unique ovarian cancer biomarkers ovarian specific cDNA microarray analysis identified hRad17 a cell cycle checkpoint protein as over-expressed in ovarian cancer. The aim of this study was to validate this expression. Methods Immunohistochemistry was performed on 72 serous 19 endometrioid 10 clear cell and 6 mucinous ovarian cancers 9 benign ovarian tumors and 6 normal ovarian tissue sections using an anti-hRad17 antibody. Western blot analysis and quantitative PCR were performed using cell lysates and total RNA prepared from 17 ovarian cancer cell lines and 6 normal ovarian epithelial cell cultures HOSE . Results Antibody staining confirmed upregulation of hRad17 in of ovarian cancer cases. Immunohistochemistry demonstrated that only 42 of serous and 47 of endometrioid subtypes showed overexpression compared to 80 of clear cell and 100 of mucinous cancers. Western blot confirmed overexpression of hRad17 in cancer cell lines compared to HOSE. Quantitative PCR demonstrated an upregulation of hRad17 RNA by fold. hRad17 RNA expression differed by subtype. Conclusions hRad17 is over-expressed in ovarian cancer. This over-expression varies by subtype suggesting a role in the pathogenesis of these types. Functional studies are needed to determine the potential role of this protein in ovarian cancer. Background Ovarian cancer is the most deadly of all gynecologic malignancies 1 . Because ovarian cancer is diagnosed in Stage III or IV in 80 of cases the prognosis is poor with only a 44 overall survival rate 1 . However when ovarian cancer is diagnosed in the earliest stage survival approaches 90 . .